Who owns Barinthus Biotherapeutics plc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BRNS from SEC Form 13F filings across 14 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 14 institutions disclosed 8.6M shares of Barinthus Biotherapeutics plc. worth $7.4M — about 21% of shares outstanding; the largest disclosed holder is M&G PLC. Source: SEC Form 13F filings, parsed by EvidInvest.
14
13F holders
$7.4M
value, 2026 filers
21%
of shares outstanding (8.6M sh)
3
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BRNS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | M&G PLC | 5.2M | $5.2M | 0.0% | 12.7% | 0.0% |
| 2 | HSG Holding Ltd | 1.4M | $937,512 | 0.1% | 3.5% | 0.0% |
| 3 | GLR Partners, LLC | 1.2M | $820,629 | 0.4% | 3% | 0.0% |
| 4 | Rangeley Capital, LLC | 185,136 | $122,190 | 0.1% | 0.5% | +16.1% |
| 5 | Johns Hopkins University | 122,237 | $80,676 | 0.0% | 0.3% | 0.0% |
| 6 | MORGAN STANLEY | 108,843 | $71,837 | 0.0% | 0.3% | +4825.0% |
| 7 | Baird Financial Group, Inc. | 105,961 | $69,934 | 0.0% | 0.3% | 0.0% |
| 8 | CITADEL ADVISORS LLC | 76,754 | $50,658 | 0.0% | 0.2% | -35.5% |
| 9 | HighTower Advisors, LLC | 37,450 | $24,717 | 0.0% | 0.1% | 0.0% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 25,000 | $16,500 | 0.0% | 0.1% | -83.4% |
| 11 | XTX Topco LtdNEW | 14,819 | $9,781 | 0.0% | 0% | new |
| 12 | RHUMBLINE ADVISERS | 11,685 | $7,712 | 0.0% | 0% | 0.0% |
| 13 | TWO SIGMA SECURITIES, LLCNEW | 11,052 | $7,294 | 0.0% | 0% | new |
| 14 | UBS Group AGNEW | 1,008 | $665 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.